Run time: 79m

  0      0

2019 AABB Annual Meeting On-Demand


ST4-24: Graft Engineering for Cell-Based Therapies: Before and Beyond CAR T Cells


Oct 19, 2019 1:30pm ‐ Oct 19, 2019 3:00pm

Expiration Date: Dec 31, 2021


Credits: None available.

Standard: $25.00
Members: $20.00

Description

Concurrent with recent success using gene-modified T cells for immunotherapy, is exciting progress in the refinement, scale-up and clinical applications of non-gene modified immune effector cells. The speakers in this session will provide state-of-the-art reviews of laboratory methodologies, manufacturing and production challenges, clinical data and the therapeutic potential of autologous and allogeneic natural killer (NK) cells, dendritic cells (DC) and T cells to treat malignant diseases.

Learning Objectives:

  • Appreciate the therapeutic potential of non-gene modified immune effector cells for the treatment of malignant diseases.
  • Identify the technical challenges and methodologies to optimize immune cell populations for adoptive immunotherapy.
  • Recognize the future directions and opportunities for broader applications of cell-based immunotherapies.


Speaker(s):

Disclosures

  • Jose Cancelas Perez, MD PhD :

    Fresenius: Grant/Research Support (Secondary Investigators need not disclose)  I  US Dept of Defense/Westat: Grant/Research Support (Secondary Investigators need not disclose)  I  Cellphire/BARDA: Grant/Research Support (Secondary Investigators need not disclose)  I  Terumo BCT: Grant/Research Support (Secondary Investigators need not disclose)  I  Hemanext: Consultant, Grant/Research Support (Secondary Investigators need not disclose)  I  Cerus Corp: Grant/Research Support (Secondary Investigators need not disclose)

  • David McKenna, MD :

    National Cord Blood Program: DSMB  I  Erytech: DSMB  I  B-MoGen Biotech: Scientific Advisory Board  I  BEST Collaborative: Team Co-Leader/Exec Comm  I  Icahn School of Medicine: Consultant  I  CIBMTR/BMT CTN: Medical Monitor  I  NIH/NEI: DSMB  I  Gamida: Clinical trial product manufacturing  I  Fate Therapeutics: Clinical trial product manufacturing  I  Intima: Clinical trial product manufacturing  I  Magenta: Clinical trial product manufacturing  I  NMDP: Donor and Patient Safety Monitoring Advisory Group  I  NIH/NHLBI: Research funding

  • David Stroncek, MD :

    Nothing to Disclose

Credits Available


ST4-24: Graft Engineering for Cell-Based Therapies: Before and Beyond CAR T Cells Evaluation

You must be logged in and own this session in order to post comments.

Print Certificate
Completed on: token-completed_on
Print Transcript
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content